ADMA Biologics

Pipeline: S. pneumoniae for treatment of pneumococcal pneumonia infections.

The Company manufactures, develops and commercializes human plasma and plasma-derived, targeted therapeutics to extend and enhance the lives of individuals who are naturally or medically immunocompromised at risk for certain infections.therapeutics for immunity-compromised patients,. ADMA andBiologics consists of ADMA BioManufacturing and ADMA BioCenters (Plasma Collection Centers).

The company has three FDA-licensed approved products:

ADMA BioManufacturing is implemented the end-to-end control of supply chain from plasma collection through plasma fractionation, purification, fill-finish and testing.

ADMA BioCenters currently consists of a network of 9 plasma collection centers in various stages of approval and development.First center opened in 2011.

The company has three FDA-licensed approved products:

ASCENIVTM (Immune Globulin Intravenous - slra, Human), is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).(Immune Globulin Intravenous - slra, Human), is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).

ASCENIV™ is a novel IG and the only product in its class produced by blending normal plasma with hyperimmune plasma using ADMA’s patented methods.

BIVIGAM® (Immune Globulin Intravenous, Human), 10% Liquid] is indicated for the treatment of primary humoral immunodeficiency (PI). This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).(Immune Globulin Intravenous, Human), 10% Liquid] is indicated for the treatment of primary humoral immunodeficiency (PI). This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).

NABI-HB® (hepatitis B immune globulin, human), is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection.(hepatitis B immune globulin, human), is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection. Nabi-HB has been used for over 20 years to protect against hepatitis B

infection among newly exposed individuals.

ASCENIV™ (Immune Globulin Intravenous - slra, Human),

BIVIGAM® (Immune Globulin Intravenous, Human),

NABI-HB® (hepatitis B immune globulin, human).

ASCENIV™ (Immune Globulin Intravenous - slra, Human), is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).

BIVIGAM® (Immune Globulin Intravenous, Human), 10% Liquid] is indicated for the treatment of primary humoral immunodeficiency (PI). This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).

NABI-HB® (hepatitis B immune globulin, human), is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection.

The Company develops and commercializes human plasma and plasma-derived therapeutics for immunity-compromised patients, and consists of ADMA BioManufacturing and Plasma Collection Centers.

Top Institutional Holders are: Perceptive Advisors Llс, Nuveen Asset Management,

Vanguard Group, Inc., Boothbay Fund Management, Blackrock Inc.

ADMA Biologics is a biopharmaceutical public company, based in New Jersey, USA. ADMA Biologics was founded in 2004.

The company has three FDA-licensed approved products:

ASCENIV™ (Immune Globulin Intravenous - slra, Human),

BIVIGAM® (Immune Globulin Intravenous, Human),

NABI-HB® (hepatitis B immune globulin, human).

Its specialty is to develop and commercialize plasma-derived, human immune globulins for the treatment and prevention of certain infectious diseases.

NASDAQ ticker is ADMA.